Mazdutide
GLP-1 / glucagon dual agonist. Mazdutide is investigational and not approved for any use.
Key facts
- Class
- GLP-1 / glucagon dual agonist
- Also called
- IBI362
- Half-life
- Not found
- No published half-life found (PubMed search, 2 Oct 2026)
- FDA status
- Not approved
- Investigational in the US (approved in China)
- WADA
- Not listed
- 2026 Prohibited List
Mazdutide guides
Explained
Evidence at a glance
Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.
| Condition | Human studies | Animal studies | Studies we summarised | Evidence grade |
|---|---|---|---|---|
| Diabetes | Not in our ledger | Not in our ledger | 3 | Human RCT evidence, 4 of 4Nature 2026, PMID 41407859 |
| Heart health | Not in our ledger | Not in our ledger | 1 | No graded study for this goal |
| Metabolism | Not in our ledger | Not in our ledger | 3 | Human RCT evidence, 4 of 4Nature 2026, PMID 41407859 |
| Weight loss | Not in our ledger | Not in our ledger | 9 | Human RCT evidence, 4 of 4JAMA 2026, PMID 42251595 |
Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.
A dual agonist: GLP-1 plus glucagon
Mazdutide (IBI362, LY3305677) is a weekly GLP-1 and glucagon receptor dual agonist.[10]
In Chinese adults with type 2 diabetes, 4 mg and 6 mg of mazdutide were non-inferior and superior to 1.5 mg dulaglutide for HbA1c change at week 28, with greater body-weight reductions.[11]
Strongest finding and what is still narrow
In the GLORY-2 trial in Chinese adults with obesity, mean body weight changed by -16.65% at week 60 on mazdutide and -1.50% on placebo.[5]
Vomiting affected 53.1% on mazdutide and 1.3% on placebo; nausea affected 46.9% and 3.2%.[5]
In a phase 2 trial, the mean 32-week weight change was -18.1% at 16 mg versus -0.9% on placebo.[12]
Regulatory path
Drugs@FDA lists no mazdutide product.[2]
The UK emc search found no mazdutide product.[13]
Common questions
Is Mazdutide FDA approved?
No. Mazdutide is investigational (investigational in the us (approved in china)) and not approved for any use.
What is mazdutide?
A weekly GLP-1 and glucagon receptor dual agonist.[10]
What does mazdutide do?
In a trial in Chinese adults it lowered body weight by a mean of 16.65% compared with 1.50% on placebo.[5]
Does mazdutide have health benefits beyond weight?
In a 28-week trial in Chinese adults with type 2 diabetes it lowered HbA1c more than dulaglutide did.[11]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "mazdutide" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 3FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 4Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 5Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.JAMA · 2026PMID 42251595Accessed 2 Oct 2026
- 6PubMed search: mazdutide[tiab] OR IBI362[tiab] OR LY3305677[tiab] (53 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: (mazdutide[tiab] OR IBI362[tiab] OR LY3305677[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (31 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: (mazdutide[tiab] OR IBI362[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (1 result)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9Mazdutide versus placebo in Chinese adults with type 2 diabetes.Nature · 2026PMID 41407859Accessed 2 Oct 2026
- 10IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.EClinicalMedicine · 2021PMID 34430840Accessed 2 Oct 2026
- 11Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.Nature · 2026PMID 41407860Accessed 2 Oct 2026
- 12Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.The lancet. Diabetes & endocrinology · 2026PMID 42628555Accessed 2 Oct 2026
- 13emc (UK) search: mazdutideElectronic Medicines Compendium (UK) · 2026medicines.org.ukAccessed 2 Oct 2026
Found an error? Report a correction.